We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Aquestive Therapeutics (AQST - Free Report) shares ended the last trading session 7.9% higher at $6.69. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 27.1% gain over the past four weeks.
The surge in stock price is likely due to positive expectations regarding the company’s key product candidate, Anaphylm, which is currently under review with the FDA for treating severe allergic reactions. Earlier this week, the United States Patent and Trademark Office (USPTO) issued two additional U.S. patents related to Anaphylm, which will extend protection into 2037.
This specialty pharmaceutical company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $13.36 million, down 1.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Aquestive Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AQST going forward to see if this recent jump can turn into more strength down the road.
Aquestive Therapeutics is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Madrigal (MDGL - Free Report) , finished the last trading session 2% lower at $428.3. MDGL has returned 1.6% over the past month.
For Madrigal, the consensus EPS estimate for the upcoming report has changed +78.4% over the past month to -$1.96. This represents a change of +60.2% from what the company reported a year ago. Madrigal currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?
Aquestive Therapeutics (AQST - Free Report) shares ended the last trading session 7.9% higher at $6.69. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 27.1% gain over the past four weeks.
The surge in stock price is likely due to positive expectations regarding the company’s key product candidate, Anaphylm, which is currently under review with the FDA for treating severe allergic reactions. Earlier this week, the United States Patent and Trademark Office (USPTO) issued two additional U.S. patents related to Anaphylm, which will extend protection into 2037.
This specialty pharmaceutical company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $13.36 million, down 1.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Aquestive Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AQST going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Aquestive Therapeutics is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Madrigal (MDGL - Free Report) , finished the last trading session 2% lower at $428.3. MDGL has returned 1.6% over the past month.
For Madrigal, the consensus EPS estimate for the upcoming report has changed +78.4% over the past month to -$1.96. This represents a change of +60.2% from what the company reported a year ago. Madrigal currently has a Zacks Rank of #3 (Hold).